Evicenter
P&T meetings

Zanzalintinib

Metastatic colorectal cancer

Also known as XL092
Manufacturer
Exelixis
Regulatory submission
NDA submitted December 2025
Launch
Not announced
65 sources

Section 6 of 6

References

65 sources

  1. American Cancer Society (2026) (opens in a new tab)
  2. ASCO (2022) (opens in a new tab)
  3. ASCO (2023) (opens in a new tab)
  4. Ashouri et al. (2025) (opens in a new tab)
  5. Bhimani et al. (2022) (opens in a new tab)
  6. Blank et al. (2011) (opens in a new tab)
  7. Burge et al. (2026) (opens in a new tab)
  8. Cann et al. (2026) (opens in a new tab)
  9. Cayman Chemical (2025) (opens in a new tab)
  10. Centers for Disease Control and Prevention (opens in a new tab)
  11. Centers for Disease Control and Prevention (opens in a new tab)
  12. Centers for Disease Control and Prevention (opens in a new tab)
  13. Dasari et al. (2023) (opens in a new tab)
  14. Dauki et al. (2026) (opens in a new tab)
  15. Eng et al. (2019) (opens in a new tab)
  16. EU Clinical Trials Register EudraCT 2021-003243-21 (opens in a new tab)
  17. Exelixis (opens in a new tab)
  18. Exelixis (opens in a new tab)
  19. Exelixis (2025) (opens in a new tab)
  20. Exelixis (2025) (opens in a new tab)
  21. Exelixis (2025) (opens in a new tab)
  22. Exelixis (2026) (opens in a new tab)
  23. Exelixis (2026) (opens in a new tab)
  24. Exelixis Form 10-K (2026) (opens in a new tab)
  25. Exelixis Form 10-Q (2026) (opens in a new tab)
  26. Exelixis Form 10-Q (2026) (opens in a new tab)
  27. Exelixis Form 8-K (2026) (opens in a new tab)
  28. Exelixis STELLAR-303 healthcare professional brochure (2023) (opens in a new tab)
  29. FDA (2023) (opens in a new tab)
  30. FDA (2023) (opens in a new tab)
  31. FDA (2023) (opens in a new tab)
  32. FDA (2025) (opens in a new tab)
  33. FDA (2025) (opens in a new tab)
  34. FDA (2026) (opens in a new tab)
  35. Fontana et al. (2025) (opens in a new tab)
  36. Fontana et al. (2025) (opens in a new tab)
  37. Garmezy et al. (2025) (opens in a new tab)
  38. Garmezy et al. (2025) (opens in a new tab)
  39. Grothey et al. (2013) (opens in a new tab)
  40. Guven et al. (2024) (opens in a new tab)
  41. Hecht et al. (2025) (opens in a new tab)
  42. Hsu et al. (2021) (opens in a new tab)
  43. Hsu et al. (2023) (opens in a new tab)
  44. Kawazoe et al. (2024) (opens in a new tab)
  45. Kiel et al. (2026) (opens in a new tab)
  46. Morris et al. (2022) (opens in a new tab)
  47. National Cancer Institute Colon Cancer Treatment PDQ (opens in a new tab)
  48. National Cancer Institute Drug Dictionary (opens in a new tab)
  49. National Cancer Institute SEER Cancer Stat Facts (opens in a new tab)
  50. Paly et al. (2024) (opens in a new tab)
  51. Patnaik et al. (2021) (opens in a new tab)
  52. Patnaik et al. (2021) (opens in a new tab)
  53. Prager et al. (2023) (opens in a new tab)
  54. Rasschaert and Tejpar (2025) (opens in a new tab)
  55. Saeed et al. (2024a) (opens in a new tab)
  56. Saeed et al. (2024b) (opens in a new tab)
  57. Saeed et al. (2025) (opens in a new tab)
  58. Shankaran et al. (2022) (opens in a new tab)
  59. Sharma et al. (2022) (opens in a new tab)
  60. Stintzing et al. (2025) (opens in a new tab)
  61. Strohbehn et al. (2026) (opens in a new tab)
  62. Taieb et al. (2025) (opens in a new tab)
  63. Yoshino et al. (2023) (opens in a new tab)
  64. Yoshino et al. (2023) (opens in a new tab)
  65. Yu et al. (2024) (opens in a new tab)